346 results on '"Kiso, Maki"'
Search Results
2. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
3. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
4. Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2
5. Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection
6. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
7. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents
8. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
9. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters
10. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
11. Characterization of a new SARS-CoV-2 variant that emerged in Brazil
12. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
13. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
14. Development of a Mouse-Adapted Reporter SARS-CoV-2 as a Tool for Two-Photon In Vivo Imaging
15. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
16. Neutrophil adhesion to vessel walls impairs pulmonary circulation in COVID-19 pathology
17. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
18. Genetic engineering employing MPB70 and its promoter enables efficient secretion and expression of foreign antigen in bacillus Calmette Guérin (BCG) Tokyo
19. An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants
20. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury
21. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets
22. Characterization of an EG.5.1 clinical isolate in vitro and in vivo
23. Development of a Mouse-Adapted Reporter SARS-CoV-2 as a Tool for Two-Photon In Vivo Imaging
24. Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus
25. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus
26. Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice
27. Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques
28. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
29. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors
30. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
31. Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus
32. Characterization of a Feline Influenza A(H7N2) Virus
33. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo
34. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
35. Oral intake of heat-killed Lactiplantibacillus pentosus ONRICb0240 partially protects mice against SARS-CoV-2 infection
36. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
37. A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia
38. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
39. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
40. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
41. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
42. Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy
43. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
44. Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine
45. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 clinical isolates
46. Molecular Mechanisms Underlying Oseltamivir Resistance Mediated by an I117V Substitution in the Neuraminidase of Subtype H5N1 Avian Influenza A Viruses
47. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.
48. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2
49. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
50. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.